Five Prime Therapeutics Profit Margin

The latest profit margin for FPRX is -6.4% as of December 2020. That compares with -9.22% in the prior-year period — up 30.6% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Five Prime Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FPRX's profit margin moved from -9.22% to -6.4% — a 30.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Five Prime Therapeutics's valuation or profitability profile.

Against Healthcare companies, FPRX currently prints -6.4% for profit margin, while the sector average sits near 15.58%. That is roughly 4206.2% below the sector mean. Large gaps often invite a closer look at Five Prime Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Five Prime Therapeutics converts resources into returns. At -6.4%, FPRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -9.22% in the prior-year period — up 30.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FPRX's profit margin (-6.4%), review year-over-year change from -9.22%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.